The Brain Beat Glucometer (BBG) is the blood glucose non-invasive self-monitoring device for Diabetes Mellitus sufferers. Unlike the traditional methods of monitoring blood glucose, BBG causes absolutely no pain or discomfort to the user and will immeasurably improve the quality of life of diabetic patients. It also offers significant cost savings by eliminating the need for expensive consumables, which cost the average diabetic approximately €3,118 per annum.
Brain Beat team has over 50 years cumulated research experience in the fields of biophysics, high performance computing and medicine, and over 32 years experience creating, growing and managing successful start-ups and companies in biotech industry. The company has developed a pre-production prototype and holds negotiations with large medical device manufacturers on licensing the technology to them for manufacturing and distribution of the device through their own established networks. Discussions are underway with potential key stakeholders such as LifeScan, Abbott and LG.
Head of International Projects,
Brain Beat represents a successful technology transfer of the spectroscopic technologies and the absorption spectra of glucose, which are both well known in the scientific community, to the global market. The solution of non-invasive glucometry, provided by the company, has a tremendous social impact: its implementation will drastically increase quality of life of more than 430 million diabetics around the world, helping them to control glucose level 24 hour a day.
The company’s team has a solid experience both in science and business development. Moreover, CEO of the company is familiar with the Japanese business culture and has certain level of command of the Japanese language, which will definitely be of use in establishing and maintaining relationship with potential Japanese partners.